Immunotherapy in Triple-Negative Breast Cancer

Area of Science:

• Oncology
• Immunology
• Medical Research

Background:

• Immunotherapy represents a significant advancement in cancer treatment.
• Triple-negative breast cancer (TNBC) is a challenging subtype with limited targeted therapies.
• Immune checkpoint inhibitors (ICIs) harness the immune system to fight cancer.

Purpose of the Study:

• To review current evidence and ongoing research on immunotherapy for early-stage and metastatic TNBC.
• To explore novel combination strategies involving immunotherapy with chemotherapy, targeted therapy, or radiation.
• To discuss the application of ICIs and potential future strategies across different TNBC stages.

Main Methods:

• Review of existing clinical trial data and scientific literature.
• Analysis of studies evaluating PD-1 inhibitors (e.g., pembrolizumab, atezolizumab) in TNBC.
• Examination of combination therapies and emerging treatment modalities.

Main Results:

• Pembrolizumab plus neoadjuvant chemotherapy is a standard for high-risk, early-stage TNBC.
• Pembrolizumab and atezolizumab plus chemotherapy are standards for first-line metastatic PD-L1+ TNBC, improving survival.
• Immunotherapy demonstrates durable effects through immunologic memory.

Conclusions:

• Immunotherapy has shifted the paradigm for TNBC treatment.
• Combination strategies are expanding treatment options for early and advanced TNBC.
• Ongoing research aims to further optimize ICI applications and develop new therapeutic approaches for TNBC.